AU556908B2 - Hexahydronaphth(1,2-beta)-1,4-oxazines - Google Patents

Hexahydronaphth(1,2-beta)-1,4-oxazines

Info

Publication number
AU556908B2
AU556908B2 AU14448/83A AU1444883A AU556908B2 AU 556908 B2 AU556908 B2 AU 556908B2 AU 14448/83 A AU14448/83 A AU 14448/83A AU 1444883 A AU1444883 A AU 1444883A AU 556908 B2 AU556908 B2 AU 556908B2
Authority
AU
Australia
Prior art keywords
hexahydronaphth
oxazines
beta
chloroacetamidotetrahydronaphthalen
parkinsonism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14448/83A
Other languages
English (en)
Other versions
AU1444883A (en
Inventor
Victor J. Grenda
James H. Jones
David E. Mcclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1444883A publication Critical patent/AU1444883A/en
Application granted granted Critical
Publication of AU556908B2 publication Critical patent/AU556908B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
AU14448/83A 1981-11-20 1983-05-11 Hexahydronaphth(1,2-beta)-1,4-oxazines Ceased AU556908B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32334981A 1981-11-20 1981-11-20

Publications (2)

Publication Number Publication Date
AU1444883A AU1444883A (en) 1984-11-15
AU556908B2 true AU556908B2 (en) 1986-11-27

Family

ID=23258834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14448/83A Ceased AU556908B2 (en) 1981-11-20 1983-05-11 Hexahydronaphth(1,2-beta)-1,4-oxazines

Country Status (12)

Country Link
EP (1) EP0080115B1 (cg-RX-API-DMAC10.html)
JP (1) JPS5892670A (cg-RX-API-DMAC10.html)
AT (1) ATE27155T1 (cg-RX-API-DMAC10.html)
AU (1) AU556908B2 (cg-RX-API-DMAC10.html)
CA (1) CA1204745A (cg-RX-API-DMAC10.html)
DE (1) DE3276312D1 (cg-RX-API-DMAC10.html)
DK (1) DK515982A (cg-RX-API-DMAC10.html)
ES (1) ES517233A0 (cg-RX-API-DMAC10.html)
GR (1) GR77041B (cg-RX-API-DMAC10.html)
HK (1) HK66090A (cg-RX-API-DMAC10.html)
IE (1) IE54157B1 (cg-RX-API-DMAC10.html)
PT (1) PT75859B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
HU193979B (en) * 1984-06-12 1987-12-28 Sandoz Ag Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
US4774243A (en) * 1985-12-24 1988-09-27 Merck & Co., Inc. Dopamine agonists for treating elevated intraocular pressure
US4758661A (en) * 1986-06-24 1988-07-19 Merck & Co., Inc. Chiral synthesis of (+)-trans-1a,2,3,4a,5,6-hexahydro-9-hydroxy-4-propyl-4H-naphth[1,2-b]-1,4-oxazine
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4743601A (en) * 1987-07-13 1988-05-10 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-1,4-oxazino(2,3-C)quinolines
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
FR2721027B1 (fr) * 1994-06-08 1996-07-19 Adir Nouveaux dérivés tétracycliques de la 1,4-oxazine, leur procédé de préparation et les compositions pharmaceutiques les contenant.
FR2767825A1 (fr) * 1997-09-01 1999-02-26 Adir Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2007009847A (es) * 2005-02-14 2008-03-10 Clera Inc Phno fluorada y analogos de ella.
FR2906249B1 (fr) * 2006-09-26 2008-12-19 Servier Lab Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
GB0821432D0 (en) * 2008-11-24 2008-12-31 Gen Electric Imaging ligands
CN102898397B (zh) * 2012-09-26 2014-12-10 江苏华益科技有限公司 (4aR,10bR)-3,4,4a,5,6,10b-六氢-2H-萘并[1,2-b][1,4]噁嗪-9-醇类物质及其盐酸盐合成方法
AU2016378650B2 (en) * 2015-12-22 2020-12-24 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as S1P modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642789A (en) * 1970-02-13 1972-02-15 Dow Chemical Co Indeno(1 2-b)-1 4-oxazines
US4238486A (en) * 1979-11-23 1980-12-09 Merck & Co., Inc. Indolobenzoxazines

Also Published As

Publication number Publication date
CA1204745A (en) 1986-05-20
GR77041B (cg-RX-API-DMAC10.html) 1984-09-04
PT75859B (en) 1986-01-21
DE3276312D1 (en) 1987-06-19
JPS5892670A (ja) 1983-06-02
HK66090A (en) 1990-08-31
ATE27155T1 (de) 1987-05-15
AU1444883A (en) 1984-11-15
PT75859A (en) 1982-12-01
IE54157B1 (en) 1989-07-05
IE822755L (en) 1983-05-20
EP0080115B1 (en) 1987-05-13
ES8401048A1 (es) 1983-12-01
ES517233A0 (es) 1983-12-01
DK515982A (da) 1983-05-21
EP0080115A3 (en) 1984-07-18
EP0080115A2 (en) 1983-06-01
JPH0347270B2 (cg-RX-API-DMAC10.html) 1991-07-18

Similar Documents

Publication Publication Date Title
AU556908B2 (en) Hexahydronaphth(1,2-beta)-1,4-oxazines
ATE171056T1 (de) Verbindungsanordnung eines dentalimplantats mit einem konus-sekundärteil
EP0506636A3 (en) Temporary cylinder
CA2152049A1 (en) Telemetry system and apparatus
DE59006880D1 (de) Gerät zur Herstellung von Formkörpern und Verwendung desselben zur Herstellung von Inlays, Onlays, und Kronen in der Zahnmedizin.
GR3005447T3 (cg-RX-API-DMAC10.html)
IL110672A0 (en) Therapeutic heterocycles
DE3886986D1 (de) Glykoprotein, Verfahren zu dessen Herstellung und dieses als aktiven Bestandteil enthaltendes immunsuppressives Agens.
DE3650264D1 (de) Aluminiumnitridsinterkörper und Verfahren zu seiner Herstellung.
DE3671451D1 (de) 4h-triazolo (4,3-a)(1,4) benzodiazepine, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
NO891151D0 (no) Arylpiperazinylalkoksyderivater av cykliske imider, samt fremgangsmaate for fremstilling derav.
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
AU622010B2 (en) Substituted 1,8-naphthyridines
AR244756A1 (es) Nuevos monomeros y polimeros coloreados, procedimiento de preparacion de dichos polimeros y procedimiento de separacion de sustancias biologicamente activas mediante el uso de dichos polimeros.
AU7504987A (en) Novel tricyclic derivatives which are agonists of cholinergic receptors, and drugs in which they are present
IL83814A (en) 10-(cyclic)amino-9-halo-7-oxo-2,3-dihydro-7h-pyrido(3,2,1-ij)-1,3,4-benzoxadiazine-6-carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them and some intermediates therefor
PH23384A (en) Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions and method use thereof
DE3882870D1 (de) Polymer oder copolymer eines olefins und dessen herstellung.
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
ATE147742T1 (de) 8-alpha-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel
ATE36329T1 (de) 5,6-dihydro-4h-cyclopenta(b)thiophen-6carbons|ure, verfahren zur herstellung und sie enthaltende arzneimittel.
DE69030980D1 (de) Halbleiteranordnung mit CCD und dessen peripheren Bipolartransistoren und Verfahren zu dessen Herstellung
EP0811385A3 (en) Conjugate of a factor specifically recognizing interleukin-2 receptor with ribonuclease
AU4820990A (en) Substituted 3-azabicyclo(3.1.1)heptanes, their production and use
AU4096889A (en) The use of lactam derivatives in the treatment of depression